Lantern Pharma

Lantern Pharma

  • Founded: 2013
  • Location: Dallas, TX
  • Employee range: 50 - 200
  • Clinical stage: Clin2
  • Therapy area: NSCLC
  • Drug types: ONC, PED
  • Lead product: LP-300
  • Product link:
  • Funding: $26.25M IPO Jun 2020; $3.7M A May 2017

job board

Short description:

Personalized cancer therapy

Drug notes:

Elraglusib Clin2 solid tumors; LP-100 Clin1 oncology; TTC-352 Clin1 breast cancer; LP-184 3 efforts Clin0/Clin1 multiple cancers; LP-284 2 efforts Clin0 NHL; STAR-001 4 efforts Clin0 multiple cancers; undisclosed RD solid tumors

Long description:

Lantern Pharma is developing new classes of precision cancer drugs with novel mechanisms of action. Through the use of AI, machine learning and genomics, Lantern is transforming the cost, pace and timeline of oncology drug development. RADR, or Response Algorithm for Drug Positioning and Rescue, is Lantern’s proprietary platform that is used primarily to predict the potential response patients will have to Lantern’s drugs. This approach is central to precision medicine, to personalize cancer treatments for the individual and improve the likelihood of clinical success. However, Lantern is also using RADR to help define and develop combination strategies for a range of oncology indications.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy